CommercialCoverageMedium impact
Hematopoietic Cell Transplantation for Myelodysplastic Syndrome (CPB 0836, reviewed 2025-12-09)
Aetna·Hematology, Oncology, Internal Medicine +1 more·Medical Policy
Effective date
Dec 9, 2025
We identified it
Aug 17, 2026
Summary
Aetna's CPB 0836 clarifies medical necessity coverage for hematopoietic cell transplantation (HCT) in myelodysplastic syndrome (MDS). Allogeneic HCT is covered for intermediate/high-risk MDS patients who failed prior therapy with an HLA-compatible donor; repeat allogeneic HCT is covered for graft failure or late relapse (>18 months). Autologous HCT and early relapse repeat HCT remain experimental/unproven and non-covered.
Action Required
Immediate action required: Billing team must update authorization and billing rules in system to distinguish covered vs. non-covered HCT scenarios for MDS. (1) For CPT 38205, 38230, 38240, 38242, and S2150: Require prior authorization documentation confirming patient has intermediate-risk or high-risk MDS (ICD-10 D46.0-D46.9), failed prior therapy, and HLA-compatible donor available before claim submission. (2) For repeat HCT using same codes: Require prior auth with documentation of primary graft failure, failure to engraft, or late relapse (>18 months post-HCT). (3) Deny/reject all claims for CPT 38206, 38232, 38241 (autologous HCT) with ICD-10 D46.x diagnosis codes as experimental/investigational and non-covered. (4) Deny all repeat allogeneic HCT claims (CPT 38205, 38230, 38240, 38242) when documentation shows early relapse (<18 months) as experimental/investigational. (5) Update provider communication and prior auth forms to reference this specific policy (CPB 0836, effective 2025-12-09). Providers, oncology billing staff, and authorization specialists must implement these rules to prevent claim denials.